Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.
Dr. Taylor's aim is to bridge the gap between the ability to detect mutations in tumors and the accurate interpretation of their impact on the evolution of disease and then apply that knowledge to personalize the care of individual glioma patients. His current position at Loxo Oncology at Lilly brings together the focus and spirit of a biotech with the scale and resources of large pharma, with the goal of rapidly delivering impactful new medicines for people with cancer. Their approach centers on creating new medicines that unequivocally work early in clinical development and will matter to patients with the intention to curate a balanced pipeline of medicines, either internally or externally discovered, with the potential to treat cancer with dramatic effect.